The stock of Cardlytics Inc (NASDAQ: CDLX) has decreased by 0.00 when compared to last closing price of 2.50.Despite this, the company has seen a loss of -7.06% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-28 that NEW YORK, NY / ACCESS Newswire / February 28, 2025 / If you suffered a loss on your Cardlytics, Inc. (NASDAQ:CDLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cardlytics-lawsuit-submission-form?prid=133028&wire=1 or contact Joseph E. Levi, Esq.
Is It Worth Investing in Cardlytics Inc (NASDAQ: CDLX) Right Now?
Additionally, the 36-month beta value for CDLX is 1.64. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for CDLX is 48.30M and currently, short sellers hold a 17.24% ratio of that float. The average trading volume of CDLX on February 28, 2025 was 854.08K shares.
CDLX’s Market Performance
CDLX stock saw a decrease of -7.06% in the past week, with a monthly decline of -20.89% and a quarterly a decrease of -37.81%. The volatility ratio for the week is 10.80%, and the volatility levels for the last 30 days are 8.51% for Cardlytics Inc (CDLX). The simple moving average for the past 20 days is -18.39% for CDLX’s stock, with a -50.79% simple moving average for the past 200 days.
Analysts’ Opinion of CDLX
Many brokerage firms have already submitted their reports for CDLX stocks, with Evercore ISI repeating the rating for CDLX by listing it as a “In-line.” The predicted price for CDLX in the upcoming period, according to Evercore ISI is $4 based on the research report published on October 11, 2024 of the previous year 2024.
Northland Capital, on the other hand, stated in their research note that they expect to see CDLX reach a price target of $5. The rating they have provided for CDLX stocks is “Market Perform” according to the report published on August 16th, 2024.
BofA Securities gave a rating of “Underperform” to CDLX, setting the target price at $3.50 in the report published on August 15th of the previous year.
CDLX Trading at -24.92% from the 50-Day Moving Average
After a stumble in the market that brought CDLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.82% of loss for the given period.
Volatility was left at 8.51%, however, over the last 30 days, the volatility rate increased by 10.80%, as shares sank -19.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.37% lower at present.
During the last 5 trading sessions, CDLX fell by -9.00%, which changed the moving average for the period of 200-days by -72.21% in comparison to the 20-day moving average, which settled at $3.06. In addition, Cardlytics Inc saw -32.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDLX starting from Gupta Amit, who sale 54,565 shares at the price of $3.18 back on Feb 19 ’25. After this action, Gupta Amit now owns 364,072 shares of Cardlytics Inc, valued at $173,462 using the latest closing price.
Gupta Amit, the Chief Executive Officer of Cardlytics Inc, sale 46,857 shares at $3.40 during a trade that took place back on Feb 18 ’25, which means that Gupta Amit is holding 418,637 shares at $159,220 based on the most recent closing price.
Stock Fundamentals for CDLX
Current profitability levels for the company are sitting at:
- -0.66 for the present operating margin
- 0.44 for the gross margin
The net margin for Cardlytics Inc stands at -0.94. The total capital return value is set at -0.8. Equity return is now at value -186.12, with -53.09 for asset returns.
Based on Cardlytics Inc (CDLX), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at -0.04. The debt to equity ratio resting at 3.18. The interest coverage ratio of the stock is -23.67.
Currently, EBITDA for the company is -99.0 million with net debt to EBITDA at -0.65. When we switch over and look at the enterprise to sales, we see a ratio of 0.97. The receivables turnover for the company is 2.68for trailing twelve months and the total asset turnover is 0.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
In conclusion, Cardlytics Inc (CDLX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
